CALQUENCETM Cares

CALQUENCE Cares was created to provide you with education and support during treatment.

Sign up today to receive:

  • Information about treatment with CALQUENCE
  • Regular emails with helpful information on managing your treatment

Should questions come up about CALQUENCE, call 1-800-236-9933. Remember, your healthcare provider is your first source of care and information—they should always be contacted for medical advice and treatment.

To sign up, fill out the form below or call 1-800-236-9933.

patient-survey

SIGN UP FOR MORE INFORMATION

I am a ...

Have you received a CALQUENCETM Cares Starter Kit?

 

Yes, I would be willing to talk with an AstraZeneca representative about sharing my experience on CALQUENCE with AZ employees and/or with other blood cancer patients. (Optional)

*Required fields.

By completing this registration, I confirm that I am 18 years of age or older and a US resident. I understand that I may also receive ongoing information and support related to CLL/SLL, including treatment information.

AstraZeneca respects your personal health information. The information you provide may be used to send you health-related materials and to develop products, services, and programs. AstraZeneca, or third parties working on our behalf, will not sell or rent personal health information. If, in the future, you no longer want to receive health-related materials, call 1-800-236-9933. Please visit azprivacynotice.com to review our Privacy Policy.

 
 

For additional information or assistance, call 1-800-236-9933.

ASTRAZENECA ACCESS 360TM

Getting CALQUENCE after your doctor prescribes it should be easy, and we’re here to help. We can help answer questions about:

  • Insurance coverage for your medicine
  • Your out-of-pocket costs
  • Financial support
  • Pharmacies that stock or deliver your medicine
  • Nurse and other educational help

To learn more about the AstraZeneca Access 360 program, please visit MyAccess360.com or call 1-844-ASK-A360 (1-844-275-2360), Monday–Friday, 8 AM–8 PM ET.

CALQUENCE PATIENT SAVINGS PROGRAM FOR ELIGIBLE COMMERCIALLY INSURED PATIENTS

The goal of the CALQUENCE Patient Savings Program is to assist eligible patients with their out-of-pocket costs for CALQUENCE.

Most eligible patients will pay as little as $0 per month and may have access to up to $26,000 per year to assist with out-of-pocket costs related to CALQUENCE. There are no income requirements to participate in the program.

Patient Savings Program Icon

ELIGIBILITY REQUIREMENTS

Eligibility Requirements Icon
  • Patients must be residents of the United States or Puerto Rico
  • Patients must have commercial health insurance that covers medication costs for CALQUENCE, but not the full cost to the patient

Talk to your doctor or pharmacist, who can help you enroll in the program and file claims on your behalf. For additional information, please visit AstraZenecaSpecialtySavings.com or call Access 360 at 1-844-ASK-A360 (1-844-275-2360).

Patients are ineligible if prescriptions are paid by any state or other federally funded programs, including, but not limited to, Medicare Part B, Medicare Part D, Medicaid, Medigap, VA or TRICARE, or where prohibited by law. Eligibility rules apply. Additional restrictions may apply.

The CALQUENCE Patient Savings Program covers the cost of the drug only, and does not cover costs for office visits, or any other associated costs.

Offer is invalid for claims and transactions more than 120 days from the date of service.

Download our Affordability Brochure.

Talk to your doctor or pharmacist, who can help you enroll in the program and file claims on your behalf. For additional information, please visit AstraZenecaSpecialtySavings.com or call Access 360 at 1-844-ASK-A360 (1-844-275-2360).

CALQUENCETM CONNECTIONS

CALQUENCE Connections tells the stories of real patients who are taking CALQUENCE, giving you the chance to learn about treatment from people with firsthand experience. Below, find the stories of these patients.

Calquence Resources

SUPPORT ORGANIZATIONS

As handy as this website may be, there are plenty of additional resources that you can tap into, like those from the reputable and well-known organizations and cancer institutions below.

American Cancer Society

cancer.org

The American Cancer Society offers programs, support, and information. Learn about treatment options, get advice on coping with side effects, and get answers to questions about health insurance, free services, and much more.

Cancer.Net

cancer.net

Cancer.Net was created by the American Society of Clinical Oncology (ASCO) to provide expertise and information about cancer and treatment to patients and their families, so they can make informed health care decisions.

CLL Society

cllsociety.org

The CLL Society is a patient-centric, physician-curated resource for patients with CLL and their caregivers. In addition to providing helpful information, the CLL Society is dedicated to helping meet the unmet needs of those with CLL.

Leukemia & Lymphoma Society (LLS)

lls.org

LLS is a source for free blood cancer information, education, and support for patients, survivors, families, and healthcare professionals. LLS has chapters across the US.

Lymphoma Research Foundation (LRF)

lymphoma.org

LRF is the nation’s largest health organization devoted exclusively to funding innovative lymphoma research and providing support and services to people with lymphoma, their families, and caregivers.

National Comprehensive Cancer Network® (NCCN®)

nccn.org/patients/guidelines/cll

NCCN Guidelines for Patients®, translations of the NCCN clinical guidelines, are meant to help patients with cancer talk with their physicians about the best treatment options for their disease.

This content is not currently available for your device.

X


This content is not currently available for your device.

X


Important Safety Information

Important Safety Information About CALQUENCE® (acalabrutinib) capsules
+

Before taking CALQUENCE, tell your healthcare provider about all of your medical conditions, including if you:

  • have had recent surgery or plan to have surgery. Your healthcare provider may stop CALQUENCE for any planned medical, surgical, or dental procedure.
  • have bleeding problems.
  • have or had heart rhythm problems.
  • have an infection.
  • have or had liver problems, including hepatitis B virus (HBV) infection.
  • are pregnant or plan to become pregnant. CALQUENCE may harm your unborn baby and cause problems during childbirth (dystocia).
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with CALQUENCE
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with CALQUENCE and for at least 1 week after the last dose of CALQUENCE
  • are breastfeeding or plan to breastfeed. It is not known if CALQUENCE passes into your breast milk. Do not breastfeed during treatment with CALQUENCE and for at least 2 weeks after your final dose of CALQUENCE.

Important Safety Information About CALQUENCE® (acalabrutinib) capsules
+

Before taking CALQUENCE, tell your healthcare provider about all of your medical conditions, including if you:

  • have had recent surgery or plan to have surgery. Your healthcare provider may stop CALQUENCE for any planned medical, surgical, or dental procedure.
  • have bleeding problems.
  • have or had heart rhythm problems.
  • have an infection.
  • have or had liver problems, including hepatitis B virus (HBV) infection.
  • are pregnant or plan to become pregnant. CALQUENCE may harm your unborn baby and cause problems during childbirth (dystocia).
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with CALQUENCE
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with CALQUENCE and for at least 1 week after the last dose of CALQUENCE
  • are breastfeeding or plan to breastfeed. It is not known if CALQUENCE passes into your breast milk. Do not breastfeed during treatment with CALQUENCE and for at least 2 weeks after your final dose of CALQUENCE.

Tell your healthcare provider about all the medicines you take, including prescription and over-the­-counter medicines, vitamins, and herbal supplements. Taking CALQUENCE with certain other medications may affect how CALQUENCE works and can cause side effects. Especially tell your healthcare provider if you take a blood thinner medicine.

How should I take CALQUENCE?

  • Take CALQUENCE exactly as your healthcare provider tells you to take it.
  • Do not change your dose or stop taking CALQUENCE unless your healthcare provider tells you to.
  • Your healthcare provider may tell you to decrease your dose, temporarily stop, or completely stop taking CALQUENCE if you develop certain side effects.
  • Take CALQUENCE 2 times a day (about 12 hours apart).
  • Take CALQUENCE with or without food.
  • Swallow CALQUENCE capsules whole with a glass of water. Do not open, break, or chew capsules.
  • If you need to take an antacid medicine, take it either 2 hours before or 2 hours after you take CALQUENCE.
  • If you need to take certain other medicines called acid reducers (H2-receptor blockers), take CALQUENCE 2 hours before the acid reducer medicine.
  • If you miss a dose of CALQUENCE, take it as soon as you remember. If it is more than 3 hours past your usual dosing time, skip the missed dose and take your next dose of CALQUENCE at your regularly scheduled time. Do not take an extra dose to make up for a missed dose.

What are the possible side effects of CALQUENCE?

CALQUENCE may cause serious side effects, including:

  • Serious infections can happen during treatment with CALQUENCE and may lead to death. Your healthcare provider may prescribe certain medicines if you have an increased risk of getting infections. Tell your healthcare provider right away if you have any signs or symptoms of an infection, including fever, chills, or flu-like symptoms.
  • Bleeding problems (hemorrhage) can happen during treatment with CALQUENCE and can be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs or symptoms of bleeding, including blood in your stools or black stools (looks like tar), pink or brown urine, unexpected bleeding or bleeding that is severe or you cannot control, vomit blood or vomit that looks like coffee grounds, cough up blood or blood clots, dizziness, weakness, confusion, changes in your speech, headache that lasts a long time, or bruising or red or purple skin marks
  • Decrease in blood cell counts. Decreased blood counts (white blood cells, platelets, and red blood cells) are common with CALQUENCE, but can also be severe. Your healthcare provider should do blood tests to check your blood counts regularly during treatment with CALQUENCE.
  • Second primary cancers. New cancers have happened in people during treatment with CALQUENCE, including cancers of the skin or other organs. Your healthcare provider will check you for skin cancers during treatment with CALQUENCE. Use sun protection when you are outside in sunlight.
  • Heart rhythm problems (atrial fibrillation and atrial flutter) have happened in people treated with CALQUENCE. Tell your healthcare provider if you have any of the following signs or symptoms: fast or irregular heartbeat, dizziness, feeling faint, chest discomfort, or shortness of breath

The most common side effects of CALQUENCE include headache, diarrhea, muscle and joint pain, upper respiratory tract infection, and bruising.

These are not all the possible side effects of CALQUENCE. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

You may report side effects related to AstraZeneca products by clicking here.

What is CALQUENCE?

CALQUENCE is a prescription medicine used to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

It is not known if CALQUENCE is safe and effective in children.

Please see full Prescribing Information, including Patient Information.